Skip to content

SW · ALC.SW · MEDICAL - INSTRUMENTS & SUPPLIES

Alcon Inc. (ALC.SW) intrinsic value and stock valuation

$62.28as of 2026-11-21 · Mkt cap 25.08B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alcon Inc. DCF and intrinsic value

InvestorsCraft values ALC.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALC.SW’s statements →

Alcon Inc. Graham Number

Graham Number: $45.73d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Geneva 1214 alcon.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$10.9B+9.8% 5y CAGRd
20152025
Net income
$1.03B
20152025
Free cash flow
$1.81B+47.9% 5y CAGRd
20152025
Total equity
$22B+3.2% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$10.9B$9.91B$9.46B$8.72B$8.29B
Operating income$1.42B$1.41B$1.04B$672M$580M
Net income$1.03B$1.02B$974M$335M$376M
EPSd$2.07M$2.05M$1.96M$677.6K$762.1K
Operating cash flow$2.38B$2.08B$1.39B$1.22B$1.35B
Capital expenditure-$-568.83M-$-670M-$-851M-$-745M-$-1.18B
Free cash flow$1.81B$1.41B$537M$472M$165M
Total assets$31.5B$30.3B$29.6B$29.2B$28B
Total debt$5.67B$5.14B$5.14B$5.07B$4.48B
Net debt$4.15B$3.31B$4.04B$4.09B$2.9B
Total equity$22B$21.6B$20.6B$19.7B$19.3B
Cash and short-term investments$1.61B$1.83B$1.1B$980M$1.58B
Income statement
20252024202320222021
Revenue$10.9B$9.91B$9.46B$8.72B$8.29B
Cost of revenue$4.88B$4.4B$4.21B$3.97B$3.64B
Gross profit$6.02B$5.51B$5.25B$4.75B$4.65B
Research and development expenses$1.04B$876M$859M$702M$842M
Selling, general and administrative expenses$3.61B$3.25B$3.21B$3.07B$3.08B
Other expenses-$-56.57M-$-27M$140M$306M$154M
Operating expenses$4.59B$4.1B$4.21B$4.08B$4.07B
Cost and expenses$9.47B$8.5B$8.42B$8.05B$7.71B
Interest income$0.00$84M$34M$15.3M$3M
Interest expense$213.7M$192M$189M$128M$120M
Depreciation and amortization$1.35B$1.23B$1.22B$1.12B$1.22B
Ebitda$2.78B$2.68B$2.24B$1.72B$1.76B
Operating income$1.42B$1.41B$1.04B$672M$580M
Total other income/expenses, net-$-209.52M-$-157M-$-207M-$-209M-$-162M
Income before tax$1.22B$1.26B$832M$463M$418M
Income tax expense$188.6M$238M-$-142M$128M$42M
Net income$1.03B$1.02B$974M$335M$376M
Weighted average shares outstanding$493.2M$494.6M$496.9M$491.4M$490M
Weighted average diluted shares outstanding$496.2M$497.6M$496.5M$494.4M$493.4M
Balance sheet
20252024202320222021
Cash and short-term investments$1.61B$1.83B$1.1B$980M$1.58B
Net receivables$2.17B$2.08B$2.01B$1.78B$1.81B
Inventory$2.39B$2.27B$2.32B$2.11B$1.9B
Total current assets$6.44B$6.31B$5.65B$5.19B$5.39B
Property, plant and equipment, net$5.22B$4.84B$4.72B$4.42B$4.08B
Goodwill and intangible assets$18.3B$17.5B$18B$18.7B$17.7B
Long-term investments$576.6M$751M$319M$287M$52M
Total non-current assets$25.1B$24B$24B$24B$22.6B
Total assets$31.5B$30.3B$29.6B$29.2B$28B
Accounts payable$925.4M$773M$811M$861M$903M
Short-term debt$654.6M$169M$206M$168M$174M
Deferred revenue$83.9M$73M$10M$89M$108M
Total current liabilities$3.05B$2.28B$2.48B$2.74B$2.47B
Long-term debt$5.02B$4.97B$4.93B$4.9B$4.31B
Deferred revenue, non-current$90.9M$86M$32M$0.00$772M
Total non-current liabilities$6.47B$6.52B$6.51B$6.75B$6.27B
Capital lease obligations$428.7M$497M$406M$430M$406M
Total liabilities$9.51B$8.79B$8.99B$9.53B$8.74B
Common stock$20M$20M$20M$20M$20M
Retained earnings$0.00$0.00$0.00$0.00$0.00
Accumulated other comprehensive income (loss)$22B$21.5B$20.6B$19.7B$19.2B
Total equity$22B$21.6B$20.6B$19.7B$19.3B
Total investments$657.6M$752M$326M$287M$55M
Total debt$5.67B$5.14B$5.14B$5.07B$4.48B
Net debt$4.15B$3.31B$4.04B$4.09B$2.9B
Cash flow statement
20252024202320222021
Net income$1.03B$1.02B$974M$335M$376M
Depreciation and amortization$1.4B$1.23B$1.22B$1.12B$1.22B
Stock-based compensation$0.00$150M$144M$140M$138M
Change in working capital-$-314.27M-$-189M-$-404M-$-527M-$-314M
Accounts receivable-$-135.14M-$-55M-$-110M-$-164M-$-198M
Inventory-$-163.42M-$-47M-$-271M-$-217M-$-326M
Accounts payable$121.5M-$-15M-$-51M-$-48M$60M
Net cash provided by operating activities$2.38B$2.08B$1.39B$1.22B$1.35B
Investments in property, plant and equipment-$-694.54M-$-473M-$-660M-$-745M-$-1.18B
Acquisitions, net-$-746.92M-$-220M-$-10M-$-666M$480M
Net cash used for investing activities-$-1.44B-$-1.17B-$-1.09B-$-1.87B-$-1.2B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-708.16M-$-47M-$-49M-$-50M-$-22M
Dividends paid-$-173.9M-$-130M-$-116M-$-100M-$-54M
Net cash used for financing activities-$-1.15B-$-322M-$-211M-$-8M-$-123M
Net change in cash-$-389.91M$582M$114M-$-595M$18M
Cash at end of period$1.53B$1.68B$1.09B$980M$1.58B
Operating cash flow$2.38B$2.08B$1.39B$1.22B$1.35B
Capital expenditure-$-568.83M-$-670M-$-851M-$-745M-$-1.18B
Free cash flow$1.81B$1.41B$537M$472M$165M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alcon Inc.

        Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

        CEO
        David J. Endicott
        Employees
        25.6K
        Beta
        0.70

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Alcon Inc. (ALC.SW)?

        InvestorsCraft does not currently publish an intrinsic value for ALC.SW. How the IC value is calculated.

        Is ALC.SW undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALC.SW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.